Improving survival and preventing recurrence of diffuse large B-cell lymphoma in younger patients: current strategies and future directions

@inproceedings{Karlin2013ImprovingSA,
  title={Improving survival and preventing recurrence of diffuse large B-cell lymphoma in younger patients: current strategies and future directions},
  author={Lionel Karlin and Bertrand Coiffier},
  booktitle={OncoTargets and therapy},
  year={2013}
}
Prognosis of diffuse large B-cell lymphoma (DLBCL) has considerably improved during the last decade, mainly due to the addition of rituximab to chemotherapy. However, a significant proportion of patients still experience primary refractory disease or short-term relapses, conferring poor survival. Thus, achieving first-line complete remission is of major importance, especially in young and fit patients. Current strategies are based on the age-adapted International Prognostic Index, which… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 34 references

A phase I study of DCDT2980S, an antibody-drug conjugate targeting CD22, in relapsed or refractory B-cell NHL

  • R Advani, D Lebovic, M. Brunvand
  • 54th ASH Annual Meeting and Exposition; December
  • 2012
1 Excerpt

A phase I study of the anti-CD79b antibody-drug conjugate DCDS4501 A targeting CD79b in relapsed or refractory B-cell NHL

  • M Palanca-Wessels, I Flinn, LH. Sehn
  • 54th ASH Annual Meeting and Exposition; December
  • 2012
1 Excerpt

A phase II randomized study of lenalidomide or lenalidomide and Rituximab as maintenance therapy following R-CHOP chemotherapy for patients with high-risk diffuse large B-cell lymphoma

  • NM Reddy, R Simmons, M. Caldwell
  • 54th ASH Annual Meeting and Exposition; December
  • 2012
1 Excerpt

Similar Papers

Loading similar papers…